Home » Evotec, CHDI Foundation extend ongoing Huntington's disease collaboration
Evotec, CHDI Foundation extend ongoing Huntington's disease collaboration
September 12, 2014
The CHDI Foundation, a U.S. privately-funded nonprofit biomedical research organization, has extended and restated its collaboration with Evotec, a drug discovery solutions company based in Germany, through 2017. The collaboration, which aims to find new treatments for Huntington's disease, an inherited neurodegenerative disorder, means CHDI will fund up to 52 full-time scientists at Evotec over the next three years.
The collaboration initially began in 2006 and has expanded considerably to fully leverage Evotec's integrated neuroscience platform.
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here